# Guided Therapeutics Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Guided Therapeutics Inc).

## Overview

Guided Therapeutics Inc. develops and commercializes the LuViva Advanced Cervical Scan, an electromedical device used for cervical cancer screening. The company’s business is centered on selling LuViva instruments and disposables through direct and distribution channels, while it continues to pursue regulatory approvals needed to expand commercial adoption.

## Products & services

• LuViva Advanced Cervical Scan
• LuViva instrumentation packages
• LuViva disposables and RFID chips
• Regulatory approval and clinical study support
• Distributor-led international commercialization

- **LuViva devices** (70%) — Cervical cancer screening instruments sold as instrumentation packages to hospitals, clinics, and partners.
- **Disposables and consumables** (30%) — RFID chips and related consumable components used with LuViva systems.

- LuViva Advanced Cervical Scan
- LuViva instrumentation packages
- LuViva disposables and RFID chips
- Regulatory approval and clinical study support
- Distributor-led international commercialization

## Customers

The company sells primarily to medical distributors, healthcare systems, hospitals, and clinics that use LuViva for cervical cancer screening. It is also pursuing government and public-health buyers, including the Turkish Ministry of Health, because large-scale screening programs can create recurring demand for devices and disposables.

- **Medical distributors** (primary) — Buy LuViva systems for resale and market development in approved territories.
- **Hospitals and clinics** (primary) — Purchase devices for cervical cancer screening programs and patient throughput.
- **Government health ministries** (secondary) — Evaluate LuViva for public screening programs where scale and cost matter.
- **Government hospital systems** (secondary) — Buy devices for regional deployment, such as the Sulawesi hospital system in Indonesia.

- Medical distributors that place orders and build local market access
- Hospitals and clinics using LuViva for cervical screening
- Public health ministries seeking population-scale screening tools
- Government hospital systems that can buy multiple devices at once
- International partners that help navigate approvals and sales

## Geography

Guided Therapeutics is still a small-revenue company, but its commercial focus spans the United States, China, and Europe, with additional activity in Turkey and Indonesia. Geography matters because sales depend heavily on local regulatory approvals, distributor execution, and the timing of market access in each country.

- **United States** (40%) — Core commercialization market and FDA approval focus.
- **China** (35%) — Strategic market; approval timing remains a major constraint.
- **Europe** (15%) — Distribution-led sales in approved markets.
- **Turkey** (5%) — Potential public-health screening opportunity.
- **Indonesia** (5%) — Recent orders and near-term device shipments.

- United States is a core market and the FDA approval path remains critical
- China is strategically important but depends on NMPA approval
- Europe includes approved markets such as Poland, Hungary, Romania, and Russia
- Turkey is being pursued through the Ministry of Health and clinical study work
- Indonesia has already generated orders and is a near-term fulfillment market

## Strategy

The company’s near-term strategy is to secure regulatory approvals, convert distributor relationships into shipments, and fund operations until commercialization scales. It is also trying to reduce execution risk by using external financial support, advance payments, and partner-led market entry rather than building a large direct-sales footprint too early.

- **Regulatory approvals in the U.S. and China** (short-term) — Commercial scale depends on FDA and NMPA clearance, especially for the largest target markets.
- **Distributor-led international expansion** (medium-term) — The company lacks a large direct sales infrastructure, so partners are essential for market access.
- **Cash preservation and external funding** (short-term) — The business remains loss-making and needs capital to continue operations and commercialization.

- Complete FDA work to unlock U.S. commercialization
- Pursue NMPA approval to scale China sales
- Use distributors to expand in Europe and other approved markets
- Convert signed orders into prepaid manufacturing demand
- Control cash burn while funding clinical and regulatory work

## Risks

Guided Therapeutics faces substantial regulatory, funding, and commercialization risk because its revenue base is still small and dependent on approvals that can be delayed or denied. The company also has concentration risk in a few markets and counterparties, while medical-device adoption depends on clinical acceptance, distributor performance, and manufacturing execution.

- **Regulatory approval delays** [high] — Sales depend on FDA and NMPA clearance, and delays directly push out revenue and cash generation.
- **Going concern / financing risk** [critical] — The company has recurring losses and needs additional capital to continue operations and fund studies.
- **Distributor and counterparty risk** [high] — Sales depend on partners such as SMI, Newmars, and HDMT, and one partner is in contractual default.
- **Market acceptance risk** [high] — The product must gain clinical and commercial acceptance versus existing cervical screening methods.
- **Geopolitical and country-specific market risk** [medium] — Russia and other markets may face approval, trade, or operating constraints.

- FDA and NMPA delays can postpone commercialization and cash inflows
- The company may not raise enough capital to fund operations
- Distributor defaults or weak execution can disrupt orders and collections
- Market acceptance risk remains high for a niche screening device
- Geopolitical and country-specific approval risk affects Europe and Russia

## Accounting

Revenue recognition is highly judgmental because the company recognizes sales when control transfers, while some orders remain deferred until shipment or approval milestones are met. Inventory valuation, credit-loss allowances, and fair-value measurements for equity instruments also matter because the company is early-stage, has limited sales history, and relies on estimates that can move reported results.

- **Revenue recognition timing** — Can shift revenue between quarters and affect comparability.
- **Deferred revenue** — Indicates revenue already billed or collected but not yet recognized.
- **Inventory valuation** — Can affect gross margin and operating results.
- **Fair value of equity instruments** — Can create non-cash expense volatility.

- Revenue is recognized on shipment/control transfer under ASC 606
- Deferred revenue remains material until devices are shipped
- Inventory is carried at lower of cost or net realizable value
- Credit loss allowances are small but depend on customer collectability
- Equity awards and investor instruments use valuation models

---

*Last updated: 2026-04-28T20:10:49.167303+00:00*